DiaMedica Inc.

112 articles about DiaMedica Inc.

• DiaMedica Therapeutics to Participate at Lake Street’s 7th Annual Best Ideas Growth Conference

  9/6/2023

  DiaMedica Therapeutics Inc. today announced that Rick Pauls, its President and CEO will be participating at Lake Street Capital Market’s 7th Annual Best Ideas Growth (BIG7) Conference in New York, on September 14, 2023.

• DiaMedica Therapeutics to Report Second Quarter 2023 Financial Results and Provide a Business Update August 15, 2023

  8/8/2023

  DiaMedica Therapeutics Inc. announced today that its second quarter 2023 financial results will be released after the markets close on Monday, August 14th.

• DiaMedica Therapeutics to Attend the American Academy of Neurology Summer Conference

  7/18/2023

  DiaMedica Therapeutics Inc. today announced the company will be attending the 2023 AAN Summer Conference on July 28-29, at the Minneapolis Hyatt Regency.

• DiaMedica Therapeutics Announces Closing of $37.5 Million Private Placement

  6/26/2023

  DiaMedica Therapeutics Inc. today announced the closing of its previously announced $37.5 million private placement to accredited investors.

• DiaMedica Therapeutics Announces $37.5 Million Private Placement

  6/21/2023

  DiaMedica Therapeutics Inc. today announced it has entered into definitive agreements to sell its common shares in a private placement with accredited investors.

• DiaMedica Therapeutics Announces that the FDA Has Removed The Clinical Hold On DM199 Phase 2/3 Trial For Ischemic Stroke

  6/21/2023

  DiaMedica Therapeutics Inc. announced today that the U.S. Food and Drug Administration (FDA) has removed the clinical hold placed on the investigational new drug application for its ReMEDy2 phase 2/3 clinical trial studying DM199 in the treatment of acute ischemic stroke (AIS) and that preparations are underway to resume the ReMEDy2 trial as soon as possible.

• DiaMedica Therapeutics Announces Appointment of Dr. Richard Kuntz to the Board of Directors

  5/30/2023

  DiaMedica Therapeutics Inc. today announced the appointment of Dr. Richard Kuntz to its Board of Directors effective May 30, 2023.

• DiaMedica Therapeutics to Report First Quarter 2023 Financial Results and Provide a Business Update May 16, 2023

  5/8/2023

  DiaMedica Therapeutics Inc. announced today that its first quarter 2023 financial results will be released after the markets close on Monday, May 15th.

• DiaMedica Therapeutics Appoints David Wambeke as Chief Business Officer

  4/11/2023

  DiaMedica Therapeutics Inc. today announced the appointment of David Wambeke, as Chief Business Officer (CBO).

• DiaMedica Therapeutics to Present at the Oppenheimer 33rd Annual Healthcare Conference

  3/13/2023

  DiaMedica Therapeutics Inc. today announced that Rick Pauls, its President and CEO will present a corporate overview at the virtual Oppenheimer 33rd Annual Healthcare Conference, which will take place March 13th – 15th, 2023.

• DiaMedica Therapeutics to Present at Credit Suisse 31st Annual Healthcare Conference

  10/31/2022

  DiaMedica Therapeutics Inc. today announced that Rick Pauls, its President and CEO, will present a corporate overview at the Credit Suisse 31st Annual Healthcare Conference, which will take place November 8 – 10, 2022.

• 

  DiaMedica Ischemic Stroke Program Remains on Hold with Plans for Additional Studies

  10/27/2022

  Minneapolis-based DiaMedica Therapeutics plans to conduct additional studies in order to resolve a clinical hold on its DM199 program for the treatment of acute ischemic stroke (AIS).

• DiaMedica Therapeutics Appoints Julie Daves as SVP, Clinical Development Operations

  9/14/2022

  DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for neurological disorders and kidney diseases, announced today the appointment of Julie VanOrsdel Daves, MSHS, CCRP, as Senior Vice President (SVP), Clinical Development Operations.

• 

  DiaMedica Ischemic Stroke Program Hits Another Bump in the Road

  7/7/2022

  DiaMedica Therapeutics’ Phase II/III ReMEDy2 trial is on hold by the FDA because patients were experiencing severe drops in blood pressure.

• DiaMedica Therapeutics to Report First Quarter 2022 Financial Results and Provide a Business Update May 5, 2022

  4/28/2022

  DiaMedica Therapeutics Inc. today announced that its first quarter 2022 financial results will be released after the markets close on Wednesday, May 4th.

• DiaMedica Therapeutics to Report Fourth Quarter 2021 Financial Results and Provide a Business Update March 15, 2022

  3/8/2022

  DiaMedica Therapeutics Inc. today announced that its fourth quarter 2021 financial results will be released after the markets close on Monday, March 14th .

• 

  BioSpace Movers & Shakers, Feb. 4

  2/4/2022

  Biopharma and life sciences companies strengthen their boards and leadership teams with these Movers & Shakers.

• DiaMedica Therapeutics Announces Appointment of Dominic Cundari as Chief Commercial Officer

  2/2/2022

  DiaMedica Therapeutics Inc. announced today the appointment of Dominic Cundari as Chief Commercial Officer.

• DiaMedica Therapeutics Appoints Dr. Kirsten Gruis as Chief Medical Officer

  1/5/2022

  DiaMedica Therapeutics Inc. announced today the appointment of Kirsten Gruis, M.D. as Chief Medical Officer.

• DiaMedica Therapeutics to Present at the Piper Sandler 33rd Annual Virtual Healthcare Conference

  11/17/2021

  DiaMedica Therapeutics to Present at the Piper Sandler 33rd Annual Virtual Healthcare Conference.